Allogene cema-cel posts 58.3% MRD clearance in ALPHA3 first-line LBCL consolidation study
ALLO•FDA designations and interim ALPHA3 results
- Allogene Therapeutics received FDA RMAT designation for cema-cel as first-line consolidation therapy in MRD-positive large B-cell lymphoma.
- The designations were based on interim results already presented from a futility analysis in the ongoing ALPHA3 pivotal trial.
- The analysis showed cema-cel improved disease-detection clearance versus observation, supporting its positioning as an earlier-line, off-the-shelf CAR-T option.
- FDA also granted Fast Track designation for the ALPHA3 program, setting up closer agency engagement and potential expedited development and review.
Related News
Nasdaq Composite finds support near correction territory
SPY•
Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
CBZ•
